The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

Autor: Zandbergen, I.M., Najafabadi, A.H.Z., Pelsma, I.C.M., Akker-van Marle, M.E. van den, Bisschop, P.H.L.T., Boogaarts, H.D.J., Bon, A.C. van, Burhani, B., Cessie, S. le, Dekkers, O.M., Drent, M.L., Feelders, R.A., Graaf, J.P. de, Hoogmoed, J., Kapiteijn, K.K., Klauw, M.M. van der, Nieuwlaat, W.A.C.M., Pereira, A.M., Stades, A.M.E., Ven, A.C. van de, Wakelkamp, I.M.M.J., Furth, W.R. van, Biermasz, N.R., Dutch Prolactinoma Study Grp

Publikováno v: Trials, 22(1):653. BioMed Central Ltd.
Trials, 22, 1
Trials, 22(1):653. BioMed Central
Trials, 22
Trials
on behalf of the Dutch Prolactinoma Study Group 2021, ' The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma ', Trials, vol. 22, no. 1, 653 . https://doi.org/10.1186/s13063-021-05604-y
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Trials, 22(1). BMC

Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb25cf2e5c5e1813c807c1e0b72c6a45
http://www.scopus.com/inward/record.url?scp=85115842154&partnerID=8YFLogxK